Benzinga··Djs Law GroupREGENXBIO Faces Class Action Over RGX-111 Safety Disclosures Amid FDA Clinical Hold
REGENXBIO ($RGNX) sued for alleged securities violations involving undisclosed adverse trial data on RGX-111 candidate after FDA clinical hold.
RGNXsecurities fraudclass action lawsuit